Spending on glucagon-like peptide-1 receptor agonists (GLP-1 RAs) increased from 2018 to 2023, with the largest growth rates from 2022 to 2023. Although spending for certain GLP-1 RAs increased ...

At the recently launched Alzheimer’s & Parkinson’s Diseases Conference held in Vienna, Lotte Bjerre Knudsen from Novo Nordisk ...

GLP-1 receptor agonists were associated with improved survival and reduced graft loss among kidney transplant recipients with type 2 diabetes.

Oral semaglutide, already approved for type 2 diabetes, led to a reduction in CV events in patients with established ...

Weight loss is a key effect of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), but these drugs may also provide liver ...

The number of Americans taking cutting-edge weight-loss drugs like Ozempic, Wegovy and Zepbound has skyrocketed in recent ...

Researchers identified how a brain circuit involving dopamine and GLP-1 receptor impact palatability and hedonic eating.

Findings from the American College of Cardiology 2025 Annual Scientific Session show oral semaglutide reduces the risk of heart attack, stroke, and cardiovascular death by 14% in patients with type 2 ...

Prohormone convertase 1/3 (PCSK1/3) is a key enzyme in peptide processing, giving rise to peptides such as the well-known metabolic regulator glucagon-like peptide 1 (GLP-1). To identify new ...

Trump administration's to officials, who accidently shared ‘Yemen war plans’, reportedly joined the President for a $1 million fundraising ... who were added to the Signal chat group like ...